HOME >> MEDICINE >> NEWS
OREXIGEN reports positive 24-week results for Contrave phase III obesity treatment study

San Diego, CA, September 26, 2006 -- OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that top line results for the company's lead obesity compound, ContraveTM, demonstrated significant advantages in weight loss in a 24-week multi-center, placebo-controlled phase III trial; the trial will continue unblinded for an additional 24 weeks.

Contrave is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, with one of several different doses of naltrexone, an opioid antagonist used to treat various addictive disorders. The bupropion/naltrexone combination is based on the company's underlying research into the brain's regulation of appetite and energy expenditure, which suggests that combining these two central nervous system drugs may improve the ability to initiate weight loss, and importantly, to continue weight loss by blocking the body's attempts to compensate for weight loss during the treatment. The trial is testing three different dosages of naltrexone combined with the same dosage of bupropion. In what may become the preferred dose pairing based on performance and tolerability, patients completing the 24-week trial using Contrave experienced on average an excess of 7% weight loss from baseline compared to approximately 1% weight loss from baseline on average for patients using the placebo. In addition, the Contrave combination outperformed either naltrexone or bupropion given alone, and the Contrave-associated weight loss trajectory showed no indication of reaching a plateau at the conclusion of 24 weeks of blinded therapy. These findings for Contrave are consistent with an earlier phase II proof of concept study presented at the annual meeting of the American Diabetes Association in June.

"These clinical findings are indicative of a therapeutic synergy when combi
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
26-Sep-2006


Page: 1 2 3

Related medicine news :

1. New study reports hotel guests at risk from carbon monoxide poisoning
2. MIT reports key pathway in synaptic plasticity
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. New study reports improved treatment and reduced mortality for patients with heart failure
5. Study reports changing to a low-fat diet can induce stress
6. Arsenic in chicken feed may pose health risks to humans, C&EN reports
7. Tai Chi boosts immunity to shingles virus in older adults, NIH-sponsored study reports
8. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
9. UCLA study reports conflict of interest policies and practices of major journals
10. New study on school bus safety shows injuries well exceed previous reports
11. Drug company reports should be read with caution, warn doctors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
Cached News: